Health Condition 1: null- Chronic renal failure
Conditions
Interventions
Intervention1: Primaquine: 15mg single dose
Intervention2: Primaquine: 15mg single dose
Control Intervention1: NA: NA
Control Intervention2: NA: NA
Sponsors
Self funded
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subject of either gender 2. Age between 18-60 years 3. Subjects classified by NKF-KDOQI guidelines Group 1: 15.29ml/mns/1.73sq.mt, Group 2:
Exclusion criteria
Exclusion criteria: 1. Participation in any clinical trial or investigational new drug study within 4 weeks prior to dosing 2. Donation or loss of 300ml or more of blood within 8 weeks prior to study start 3. History of asthma and chronic obstructive pulmonary disease, treated or not treated or clinically significant drug allergy, history of atopic allergy (asthma, utricaria, eczematous dermatitis) 4. Peripheral smear positive for malarial parasite 5. Any gastrointestinal disorder like diarrhea, constipation within 7 days 6. G6PD deficiency 7. Known hypersensitivity to primaquine or related drugs (e.g. iodoquinol) as per history taking 8. Persons receiving treatment with other potentially hemolytic drugs 9. Pregnancy and breast feeding 10. History of surgical portosytemic shunt
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic of primaquineTimepoint: NA | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactDr. Nithya Gogtay
Outcome results
None listed